MetaVia (NASDAQ:MTVA) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?

MetaVia Inc. (NASDAQ:MTVA) passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $1.49 and traded as high as $1.7756. MetaVia shares last traded at $1.61, with a volume of 463,190 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a research report on Monday, October 19th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.00.

MetaVia Stock Up 12.6%

The stock has a market cap of $8.31 million, a price-to-earnings ratio of -0.50 and a beta of 1.24. The company’s 50-day simple moving average is $1.49 and its 200-day simple moving average is $1.64.

About MetaVia

MetaVia, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Its work is centered on conditions such as obesity, diabetes and other disorders associated with metabolic dysfunction.

The company’s activities primarily involve the discovery, development and clinical evaluation of potential drug candidates intended to address significant unmet medical needs in metabolic health. As a development-stage biotechnology company, MetaVia’s operations are focused on research programs and advancing therapies through clinical testing rather than on commercialized products.

Publicly available information provides limited detail about MetaVia’s corporate history, geographic operations and leadership.